Payment overview · 2025
General Payments
$377.77
18 reported records · 11 companies
Healthcare provider profile · identity verified
William D Jones, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONTGOMERY, AL · NPI 1669481537
Verified facts
What the public records show
CMS Open Payments records show William D Jones, MD received $377.77 in general payments during 2025 across 18 reported records.
Amgen Inc. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.18 | 21.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.33 | 16.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.32 | 11.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.62 | 9.2% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $33.23 | 8.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.38 | 7.8% | 2 | 2025 |
| Ossur Americas, Inc. | Unresolved — no canonical attribution shown | $21.36 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.43 | 5.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.23 | 5.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.30 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.39 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.77 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $63.00 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.62 | 1 | 2025 |
Source payment records
|
|||||
| ARTISS Normalized: artiss |
Biological | Baxter Healthcare | $33.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 672 | 173 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 619 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 509 | 143 |
| Alprazolam | Alprazolam | 454 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 431 | 123 |
| Losartan Potassium | Losartan Potassium | 397 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 334 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 71 |
| Tramadol Hcl | Tramadol Hcl | 247 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 77 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 213 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 71 |
| Omeprazole | Omeprazole | 170 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 31 |
| Metformin Hcl Er | Metformin Hcl | 163 | 53 |
| Clonazepam | Clonazepam | 149 | 32 |
| Meloxicam | Meloxicam | 141 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 121 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 44 |
| Metformin Hcl | Metformin Hcl | 114 | 36 |
| Prednisone | Prednisone | 108 | 54 |
| Simvastatin | Simvastatin | 96 | 31 |
| Famotidine | Famotidine | 95 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 24 |
| Glimepiride | Glimepiride | 89 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 18 |
| Furosemide | Furosemide | 83 | 27 |
| Potassium Chloride | Potassium Chloride | 80 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 32 |
| Trazodone Hcl | Trazodone Hcl | 76 | 17 |
| Carvedilol | Carvedilol | 73 | 23 |
| Repaglinide | Repaglinide | 73 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 19 |
| Eliquis | Apixaban | 72 | 13 |
| Ezetimibe | Ezetimibe | 69 | 22 |
| Pregabalin | Pregabalin | 69 | 23 |
| Allopurinol | Allopurinol | 67 | 21 |
| Lorazepam | Lorazepam | 67 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 23 |
| Ozempic | Semaglutide | 65 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 29 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 60 | 16 |
| Dexamethasone | Dexamethasone | 58 | 33 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Lisinopril | Lisinopril | 57 | 22 |
| Lovastatin | Lovastatin | 57 | 19 |
| Montelukast Sodium | Montelukast Sodium | 57 | 16 |
| Temazepam | Temazepam | 56 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 15 |
| Clonidine Hcl | Clonidine Hcl | 50 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 13 |
| Atenolol | Atenolol | 49 | 13 |
| Mirtazapine | Mirtazapine | 49 | 14 |
| Sertraline Hcl | Sertraline Hcl | 49 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Cephalexin | Cephalexin | 46 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 41 | 13 |
| Jardiance | Empagliflozin | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Diazepam | Diazepam | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Latanoprost | Latanoprost | 36 | 13 |
| Ramipril | Ramipril | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 21 |
| Clonidine | Clonidine | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Dayvigo | Lemborexant | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.77 · 18 records | Amgen Inc. | AREXVY, ARTISS, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, KRYSTEXXA, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, UBRELVY, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error